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OBJECTIVE—We examined the role of Rictor/mammalian
target of rapamycin complex 2 (mTORC2), a key component of
the phosphotidylinositol-3-kinase (PI3K)/mTORC2/AKT signaling
pathway, in regulating both b-cell mass and function.
RESEARCH DESIGN AND METHODS—Mice with b-cell–
speciﬁc deletions of Rictor or Pten were studied to determine
the effects of deleting either or both genes on b-cell mass and
glucose homeostasis.
RESULTS—Rictor null mice exhibited mild hyperglycemia and
glucose intolerance caused by a reduction in b-cell mass, b-cell
proliferation, pancreatic insulin content, and glucose-stimulated
insulin secretion. Islets from these mice exhibited decreased
AKT-S473 phosphorylation and increased abundance of FoxO1
and p27 proteins. Conversely, Pten null (bPtenKO) mice ex-
hibited an increase in b-cell mass caused by increased cellular
proliferation and size. Although b-cell mass was normal in mice
lacking both Rictor and Pten (bDKO), their b-cells were larger
than those in the bPtenKO mice. Even though the b-cell prolifer-
ation rate in the bDKO mice was lower than in the bPtenKO mice,
there was a 12-fold increase the phosphorylation of AKT-T308.
CONCLUSIONS—PI3K/AKT signaling through mTORC2/pAKT-
S473 plays a key role in maintaining normal b-cell mass. The
phosphorylation of AKT-S473, by negatively regulating that of
AKT-T308, is essential for maintaining a balance between b-cell
proliferation and cell size in response to proliferative stimuli.
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ancreatic b-cell mass is adaptively regulated in
response to factors such as glucose, insulin, IGF-
1, placental lactogen, and glucoincretins, such as
glucagon-like peptide 1 and gastric inhibitory
polypeptide, all of which have been shown to have major
roles in modulating b-cell mass (1–3). Signaling through
the phosphotidylinositol-3-kinase (PI3K) pathway is es-
sential for these stimuli to affect changes in b-cell mass.
Prior studies have shown that an increase in PI3K signal-
ing, induced either by the deletion of phosphatase and
tensin homolog (Pten) (4) or by overexpressing AKT (5),
leads to a marked expansion of b-cell mass. Conversely, an
inhibition of PI3K signaling in b-cells, as achieved by ge-
netic deletion of either insulin receptor substrate 2 (6) or
phosphoinositide-dependent kinase 1 (PDK1) (7), dramat-
ically reduces pancreatic b-cell mass.
PI3K signaling is initiated by the production of phos-
phoinositide 3 (3,4,5)-phosphate (PI3P) from phosphoino-
sitide 2 (4,5)-phosphate (PI2P) and attenuated by the
dephosphorylation of PI3P back to PI2P by Pten (8,9). The
accumulation of PI3P recruits AKT to the cell membrane
where AKT can be activated by PDK1-mediated phos-
phorylation on a threonine (T) in the kinase domain (KD)
(T308 in AKT2) and by mammalian target of rapamycin
complex 2 (mTORC2)-mediated phosphorylation at a ser-
ine (S) in the hydrophobic motif (HM) (S473 in AKT2).
It has long been thought that the phosphorylation of
T308 and S473 sites are additive with respect to AKT ki-
nase activity, with the PDK1-dependent phosphorylation
of T308 having a dominant role (10) over the mTORC2-
dependent phosphorylation of S473. However, recent studies
have shown that the site(s) at which AKT is phosphory-
lated may modify its speciﬁcity for downstream substrates.
For instance, it has been shown that FoxO1/3a, in both
mouse embryonic ﬁbroblasts (11) and Drosophila S2 cells
(12), can only be activated by mTORC2-dependent AKT-
S473 phosphorylation. If extended to other cell types, dif-
ferential downstream signaling by AKT could explain why
PI3K signaling variably affects the size, proliferation, and
metabolism of different cell types (8). In the case of the
pancreatic b-cell, it is well known that PI3K/AKT signaling
is essential for mediating changes in b-cell mass in re-
sponse to growth factor/insulin signaling (13). However, it
is not known whether the site-speciﬁc activation of AKT at
either T308 or S473 has selective downstream effects.
To assess the role of AKT-S473 phosphorylation on PI3K
signaling in the pancreatic b-cell, we deleted Rictor, a key
component of mTORC2, thereby preventing phosphoryla-
tion of AKT at S473. Furthermore, to determine whether
the site-speciﬁc activation of AKT at either T308 or S473
has selective downstream effects, or is negatively affected
by feedback regulation (10), we explored the dynamics
of signaling through both the KD and HM sites of AKT
by simultaneously manipulating the expression of Pten.I n
this way, we were able to concurrently stimulate both
PDK1 and mTORC2 activity. Our results indicate that
phosphorylation of the KD and HM sites of AKT causes
different effects on b-cell proliferation and size. In addi-
tion, we found that AKT-T308 phosphorylation is increased
greatly by the loss of Rictor/mTORC2, suggesting the ex-
istence of a mechanism whereby the phosphorylation of
AKT-S473 inhibits that of AKT-T308.
RESEARCH DESIGN AND METHODS
Animal maintenance and genotyping. Genotyping was performed by PCR
using DNA extracted from ear or tail biopsies. The primers used for genotyp-
ing were as follows: Rictor
lox,5 9-ACTGAATATGTTCATGGTTGTG and 59-
GAAGTTATTCAGATGGCCCAGC; PTEN
lox,5 9-ACTCAAGGCAGGGATGAGC
and 59-GCCCCGATGCAATAAATA; Ins2Cre,5 9- CTCTGGCCATCTGCTGATCC
and 59-CGCCGCATAACCAGTGAAAC. To test the Cre-mediated recombina-
tion in Rictor or Pten in b-cells, genotyping was performed by PCR using DNA
extracted from islets. The primers used for genotyping were as follows: Rictor,
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ORIGINAL ARTICLEFIG. 1. Veriﬁcation of tissue-speciﬁc deletion of Rictor or Pten and effects of Rictor or Pten deﬁciency on mouse growth and glucose metabolism.
A: PCR analysis of islet DNA. Upper: Conditional Rictor and Pten alleles in which the LoxP sites are indicated by pink triangles. Expression of
Ins2Cre results in the Cre-mediated deletion of exon 3 or 5 in the Rictor or Pten genes, respectively. Lower: Photographs of PCR analysis showing the
loxed, wild-type, and deleted alleles of both genes (lane 1, bRicKO, Rictor
lox/lox; Pten
lox/WT; Ins2Cre




+; lane 3, bDKO, Rictor
lox/lox; Pten
lox/lox; Ins2Cre
+; and lane 4, Dlox, Rictor
lox/lox; Pten
lox/lox). B: Western blot analysis of protein lysates
isolated from control and mutant islets. Blots were probed with Rictor and Pten antibodies to verify the deletion of both genes. GAPDH was used as
the loading control. C: Mouse body weight and fed blood glucose (D) were measured every 4 weeks between 4 and 16 weeks of age. †P < 0.05,
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Pten,5 9-ACTCAAGGCAGGGATGAGC and 59-CTTGATATCGAATTCCTGCAGC.
Animal husbandry and experimentation were performed with approval of the
Vanderbilt Institutional Animal Care and Use Committee under supervision of
the Division of Animal Care. Mice were of a mixed genetic background of
C57BL/6, BALB/c, and 129 strains.
Blood glucose and insulin assays. Mice were injected intraperitoneally with
2 mg dextrose/g body wt or 0.75 IU insulin/kg body wt (Novo Nordisk,
Princeton,NJ)afteranovernightor6-hfast.Bloodglucoseconcentrationswere
measured using a Logic Glucose Meter (Nova Biomedical, Waltham, MA).
Plasma insulin values were determined by radioimmunoassay (Linco, St.
Charles, MO).
b-Cell proliferation and cell size. Pancreata were isolated from embryos at
embryonic day 17.5 and 3-month-old mice that were fed with water containing
BrdU (0.08%, Sigma Aldrich, St. Louis, MO) for 1 week. Parafﬁn sections were
labeled by anti-insulin, anti-BrdU, anti-Ki67, or anti-Glut2 antibodies (additional
details in Supplementary Table 1). Insulin and BrdU or Ki67 double positive
cells were counted as proliferating b-cells for each genotype (4,14) by Image J
(National Institutes of Health, Bethesda, MD). b-Cell size was determined by
measuring the internal area of islet cells as deﬁned by Glut2 labeling using
Metamorph version 7.1.0 (Molecular Devices, Sunnyvale, CA) (15).
b-Cell mass and insulin content. Pancreata were removed from 3-month-old
mice, weighed, and then either embedded or homogenized. Parafﬁn tissue
sections (every 250 mm, 5–15 sections per sample) were analyzed as previously
described (15). Pancreatic homogenates were stored at 220°C until a radio-
immunoassay for insulin concentration and protein assay (bicinchoninic acid
assay, Thermo Fisher Scientiﬁc, Waltham, MA) were carried out for insulin
content measurement.
Immunoﬂuorescence and immunohistochemical staining. Antibodies used
for immunochemistry are listed in Supplementary Table 1. Images were cap-
tured using a Zeiss Axioplan-2 upright microscope equipped with Q capture
software (Molecular Devices, Sunnyvale, CA) or a Zeiss LSM 510 confocal
microscope. Diaminobenzidine staining was performed using a diaminobenzidine
peroxidase substrate kit (Vector Laboratories, Burlingame, CA).
Islet isolation and in vitro culture. Pancreata were digested by collagenase
P, previously described for islet isolation (16). Isolated islets were then cul-
tured overnight in Roswell Park Memorial Institute medium with 11.1 mmol/L
glucose and 10% FBS. The next morning, they were washed and incubated in
Roswell Park Memorial Institute medium with 5.6 mmol/L glucose and 0.5%
BSA for an additional 4 h and then collected and stored at 280°C until ana-
lyzed (7).
Immunoblot analysis. Islet proteins were extracted, and protein concentra-
tion was determined using the BioRad DC reagent (Hercules, CA). For im-
munoblotting, islet extracts were subjected to SDS-PAGE before proteins were
transferred electrophoretically to nitrocellulose membranes. Antibodies used
for immunoblotting are listed in Supplementary Table 1. Densitometry quan-
tiﬁcation was performed with Image J.
RNA isolation and real-time quantitative RT-PCR. RNA from freshly
isolated islets was extracted using Trizol (Invitrogen, Carlsbad, CA) and further
puriﬁed with DNA-free kits (Zymo Research, Orange, CA). RNA concentration
and integrity were determined using both a ND-1000 Spectrophotometer
(NanoDrop, Wilmington, DE) and an Agilent Bioanalyzer (Agilent Technolo-
gies, Inc., Santa Clara, CA). cDNA was made using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA). Real-time PCR
was performed by custom-designed TaqMan Gene Expression Assay in a
7900HT Fast Real-Time PCR System (Applied Biosystems). The primer and
probe sets used are listed in Supplementary Table 2.
Islet perifusion assay. Islets were placed in perifusion chamber at 37°C and
perifused with Dulbecco’s modiﬁed Eagle’s medium at a rate of 1 mL/min (17).
Islets were pre-equilibrated with media containing 5.6 mmol/L glucose for
30 min and then perifused with 5.6 mmol/L glucose for 10 min, 16.7 mmol/L
glucose for 10 min, and 5.6 mmol/L glucose for another 20 min. Fractional
insulin content was determined using a radioimmunoassay kit (Linco Re-
search, St. Louis, MO). At the end of each perifusion study, the islets were
collected and lysed with acid ethanol to measure total insulin content. The
results are presented as insulin secreted normalized to 100 islet equivalents.
The area under the curve was calculated for the interval between 10 and
30 min of perifusion.
b-Cell apoptosis. TdT-mediated X-dUTP nick-end labeling (TUNEL) was
performed on serial pancreatic sections by using In Situ Cell Death Detection
and Fluorescein kits (Roche, Basel, Switzerland). Cells were immunolabeled
for insulin after TUNEL. Insulin and TUNEL double-positive cells within
pancreatic islets were then counted and analyzed.
Statistical analysis. Statistical calculations were performed with SPSS 11.0
(SPSS Inc., Chicago, IL). Group comparisons were analyzed by Student t test
and one-way ANOVA. Data are presented as mean 6 SEM.
RESULTS
b-Cell–speciﬁc deletion of Rictor or Pten in mice. To
eliminate the expression of Rictor/mTORC2 or Pten in a
b-cell–speciﬁc manner, we intercrossed mice containing
conditional Rictor (Rictor
lox) (18) or Pten alleles (Pten
lox)
(4) with animals bearing an Ins2Cre transgene to generate
mice that were null for Rictor (bRicKO), null for Pten
(bPtenKO), null for both Rictor and Pten (bDKO), het-
erozygous for both Rictor and Pten (bDhet), or homozy-
gous for both conditional alleles (Dlox). Both bDhet and
Dlox mice served as controls. To assess whether recom-
bination was occurring in both the Rictor
lox and Pten
lox
alleles, we performed PCR analysis using DNA extracted
from islets and primers that ﬂanked the recombination
sites. As shown in Fig. 1A, DNA isolated from Dlox islets
showed no evidence of recombination in either allele,
whereas DNA fragments of the predicted sizes were ob-
served in both single and double allele knock-out (KO) mice.
Although bands representing unrecombined alleles were
seen in the bRicKO, bPtenKO, and bDKO mice, they were
likely due to the presence of non–b-cells in islets and in-
complete recombination by the Ins2Cre transgene, as
suggested by the detection of Cre in 56.2 6 2% and 55.6 6
3% of b-cells at embryonic day 17.5 and 12 weeks of age,
respectively. Thus, to further conﬁrm that the Cre-mediated
recombination in Rictor and Pten reduces the expression
of these proteins, we performed immunoblot analysis of
protein lysates from isolated pancreatic islets. As shown in
Fig. 1B, there was a reduction in the amount of both Rictor
and Pten in islets containing the Ins2Cre transgene. Mice
of all genotypes were viable and exhibited normal fertility;
however, the growth rates of both the bPtenKO and bDKO
mice differed from those of the other three genotypes
(Fig. 1C), presumably as a result of the well-documented
expression of the Ins2Cre transgene in the hypothala-
mus (4).
bPtenKO vs. other groups; ‡P < 0.05, bPtenKO and bDKO vs. other groups. #P < 0.05, bRicKO vs. bPtenKO and Dlox;* P < 0.05, bRicKO vs. all
other groups. Purple diamonds, bhet (n =1 2 –24); blue squares, bPtenKO (n=7–20); green triangles, bRicKO (n=10–19); red circles, bDKO (n=
13–37); and black squares, Dlox (n=13–23). E: Intraperitoneal glucose tolerance test. Blood glucose concentrations were tested 0, 15, 30, 60, and
120 min after glucose injection. Blood glucose in bRicKO mice was signiﬁcantly higher than Dlox at 15 and 30 min. bDKO mice had signiﬁcantly
improved blood glucose concentration compared with bRicKO at 30 and 60 min. #P < 0.05, bRicKO vs. bPtenKO and Dlox;* * P < 0.01, bRicKO vs.
all other groups, bDhet (n=13), bPtenKO (n=7), bRicKO (n=15), bDKO (n=9), and Dlox (n=13). F: AUGC and IAUGC were calculated
following the trapezoid rule, to evaluate total blood glucose excursion after a glucose bolus. IAUGC was equal to AUGC minus the area beneath the
fasting concentrations. bRicKO mice had higher AUGC and IAUGC value than Dlox. AUCG and IAUGC in bDKO mice showed signiﬁcant im-
provement compared with bRicKO. G: Curve of in vivo glucose-stimulated insulin secretion at 0, 15, and 30 min after glucose injection. Insulin
secretion after peritoneal glucose injection in the bRicKO mice trended lower at 15 min compared with the Dlox. Insulin secretion between
bRicKO and bDKO mice showed no signiﬁcant difference. bPtenKO mice had the lowest insulin secretion at 15 min after glucose bolus. *P < 0.05,
bPtenKO and Dlox vs. all other groups; **P < 0.05, bPtenKO vs. all other groups, bDhet (n=13), bPtenKO (n=7), bRicKO (n=15), bDKO (n =9 ) ,
and Dlox (n=13). H: Curve of insulin secretion per 100 islet equivalents in ex vivo perifusion test in all genotypes. Isolated islets were incubated
with 5.6 mmol/L and 16.7 mmol/L glucose, and insulin secretion was measured every 3 min up to 42 min (n=3). *P < 0.05, bRicKO and bPtenKO vs.
Dlox;* * P < 0.01, bRicKO and bPtenKO vs. Dlox. All data presented as mean 6 SEM. EE, extended exposure. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 829FIG. 2. Effects of Rictor or Pten deﬁciency on pancreatic islet characteristics and insulin content. Parafﬁn sections from 3-month-old mice were
immunolabeled with insulin and BrdU, Ki67, or Glut2. A: b-Cell mass adjusted for body weight. bPtenKO mice showed higher b-cell mass when
compared with other groups. bRicKO showed a signiﬁcantly reduced b-cell mass compared with control group. *P < 0.05; **P < 0.01. B: Whole
pancreatic insulin content was compared among all the groups. bRicKO showed the lowest insulin content among all genotypes. *P < 0.05. C:
Quantiﬁcation of the percentage of b-cells labeled for both Ki67 and insulin. bRicKO had lowest percentage of double-labeled cells. At least 1,000
cells from three embryonic pancreata were counted for each genotype to determine the number of insulin positive and insulin/Ki67 double-positive
cells. *P < 0.05; **P < 0.01. D: Quantiﬁcation of b-cell size. bDKO had largest cell size compared with other groups. In all cases, three to ﬁve mice
per genotype were analyzed. In total, 500–1,000 cells were counted, and there were at least three animals per group. *P < 0.05 vs. all other groups
or between indicated groups. **P < 0.01 vs. all other groups or between indicated groups. Data presented as mean 6 SEM. E: Representative
immunolabeled sections from embryonic day 17.5 pancreata for insulin (green), Ki67 (red), and Topo3 (blue) nuclear staining. Insulin/Ki67
immunolabeling in pancreatic islets was used to identify proliferating b-cells. Scale bar = 20 mm. F: Representative immunolabeled sections of
pancreas from adult mice for Glut2 (green) and DAPI (blue) nuclear staining. Glut2 was used to label the b-cell membrane to measure cell size.
Scale bar = 25 mm. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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metabolism and insulin secretion. To assess the effects
of the absence of Rictor/mTORC2 or Pten in b-cells on
glucose metabolism, we ﬁrst determined the fed blood
glucose concentration in mice between 4 and 16 weeks of
age. The bRicKO mice exhibited hyperglycemia beginning
at 12 weeks (Fig. 1D), whereas the blood glucose concen-
trations of the bDKO mice remained similar to those of the
controls. Insulin sensitivity assessed by insulin tolerance
test at 12 weeks did not differ among the four groups of
mice (Supplementary Fig. 1A and B). The bRicKO mice,
compared with both the Dlox and bDhet mice, showed
slower glucose clearance as indicated by elevated blood
glucose concentrations at 15 and 30 min after an in-
traperitoneal glucose bolus. Total glucose excursion, cal-
culated by both the area under glucose curve (AUGC) and
increment AUGC (IAUGC), were signiﬁcantly higher in the
bRicKO mice compared with the Dlox and bDhet animals
(Fig. 1E and F). Conversely, the bDKO mice showed a
signiﬁcantly lower blood glucose concentration at 30 and
60 min, and lower AUGC and IAUGC values, compared with
the bRicKO mice. In addition, despite their higher blood
glucose concentrations, the bRicKO mice had lower plasma
insulin levels 15 min after glucose challenge (Fig. 1G), and
lower total insulin output calculated by AUIC and IAUIC
(Supplementary Fig. 1C), compared with the Dlox and
bDhet mice. The bDKO mice showed a trend toward higher
insulin secretion compared with bRicKO animals, but these
differences were not signiﬁcant. Both the Dlox and bDhet
control groups showed similar glucose tolerance and in-
sulin secretion ability. To conﬁrm an insulin secretory defect
in bRicKO mice, we performed islet perifusion experiments.
A ss h o w ni nF i g .1 H and Supplementary Fig. 1D,i s l e t s
from bRicKO mice had approximately 70% lower insu-
l i ns e c r e t i o ni nr e s p o n s et o1 6 . 7m m o l / Lg l u c o s et h a n
the Dlox islets. Conversely, insulin secretion by the glucose-
stimulated bDKO islets was increased to a level simi-
l a rt ot h a to fD lox islets (Fig. 1H and Supplementary
Fig. 1D).
Effects of deleting Rictor or Pten on b-cell insulin
content and mass. Because the impaired insulin secre-
tion could be due to lower b-cell mass or inadequate in-
sulin production, we analyzed the mice for changes in
b-cell mass and insulin content (Fig. 2A and B). To take
into account the growth retardation of both bPtenKO and
bDKO mice at 12 weeks of age, b-cell mass was normal-
ized by the body weight of the animal (Fig. 2A and
Supplementary Fig. 2). The adjusted b-cell masses of the
bRicKO and bPtenKO mice were 28% lower (P , 0.01)
and 86% higher (P , 0.01), respectively, than the controls.
Moreover, b-cell mass in the bDKO mice was approxi-
mately 40% lower than that of the bPtenKO animals (P ,
0.05). The pancreatic insulin content of the bRicKO ani-
mals was ~50% less than the control mice but was
unchanged in both the bPtenKO and bDKO animals
(Fig. 2B).
Effects of deleting Rictor on b-cell proliferation and
size. To determine whether a change in the number or size
of b-cells was responsible for the changes in b-cell mass,
we also measured b-cell proliferation and cell size. Be-
cause of the very low b-cell turnover in adult mice (14),
b-cell proliferation was assessed by measuring the per-
centage of Ki67-positive b-cells at both embryonic day
17.5, a period when b-cells undergo a burst of cell pro-
liferation (19,20), and 12 weeks. As shown in Fig. 2C and E
and Supplementary Fig. 3, the number of proliferating
b-cells decreased 26% in the bRicKO mice and increased
34% in the bPtenKO mice compared with the controls (P ,
0.05), whereas the bDKO mice did not show increased
b-cell proliferation, as was seen in the bPtenKO mice. Islet
number per pancreatic unit area was unchanged in the
bRicKO mice (data not shown).
Because AKT is known to mediate antiapoptotic effects,
we also assessed whether the loss of Rictor/mTORC2 in
b-cells might lead to an increase in apoptosis. However, as
shown in Supplementary Fig. 4, there was no increase in
apoptosis in Rictor null b-cells when compared with con-
trol cells as determined by TUNEL staining.
The average b-cell size, shown in Fig. 2D and F, which
was unaffected in the bRicKO animals, was increased by
15% in the bPtenKO animals. Surprisingly, the average
b-cell size was increased by 31% in bDKO mice, which in
turn was 15% larger than that of the bPtenKO mice (P ,
0.05). The measurements of both b-cell proliferation and
cell size, as summarized in Table 1, suggest that the lack of
Rictor/mTORC2 in b-cells leads to a reduction in b-cell
mass mainly because of a decrease in b-cell proliferation.
mTORC2 is required for the activation of AKT via
S473 and signaling to downstream targets. To examine
whether AKT and its substrates transduce a proliferative
signal from mTORC2, we analyzed the phosphorylation of
AKT and FoxO1 and p27 protein levels in islet protein
extracts (Fig. 3). The phosphorylation of AKT at S473 in
bRicKO islets was diminished 70% compared with the
controls (Fig. 3A and B). We also found that the amount of
FoxO1 and p27 was approximately 1.5-fold greater than
the control in bRicKO islets (Fig. 3C and D). These ﬁnd-
ings suggest that the reduction in AKT-S473 phosphoryla-
tion, caused by the loss of mTORC2, leads to an increase in
cellular abundance of both FoxO1 and p27. The accumu-
lation of these proteins in bRicKO b-cells would be ex-
pected to reduce b-cell proliferation by slowing cell cycle
progression (21,22).
Ablation of both Rictor/mTORC2 and Pten increases
phosphorylation of AKT T308. Having conﬁrmed a re-
duction in AKT-S473 phosphorylation in the absence of
Rictor/mTORC2 and alterations in downstream targets for
AKT signaling, we next sought to determine whether the
TABLE 1












b-Cell mass ↓80% ↑86% ↓28% ― ↓40%
b-Cell proliferation ↓50% ↑34% ↓26% ― ↓35%
b-Cell size ↓20% ↑15% ― ↑30% ↑15%
Y. GU AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 831FIG. 3. Western blot and densitometry analysis of islet proteins in different genotypes. A: Western blotting for determining total and phosphor-
ylated AKT. The phosphorylation of AKT at T308 and S473, and total AKT protein were examined in islets of mutant and control groups.
B: Densitometry analysis for AKT phosphorylation. C: Immunoblot of p27 and FoxO1 using GAPDH as a loading control. D: Densitometry analysis
for p27 and FoxO1 protein adjusted with GAPDH. E: Immunoblot for phosphorylation of S6 (top) and densitometry analysis (bottom). Figures
represent blots from multiple mice in each genotype. Results are presented as relative folds of change in mutant compared with control mice.
Control is Dlox.* P < 0.05 vs. all other groups or the indicated group; **P < 0.01 vs. all other groups or indicated group; §P = 0.07. Four to ﬁve mice
were studied per groups. Data are presented as mean 6 SEM. ADU, arbitrary density unit.
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in response to the increased PI3K signaling brought about
by the deletion of Pten. The absence of Pten alone in the
b-cell (bPtenKO mice) resulted in an increase in both
pAKT-S473 (2.1-fold) and pAKT-T308 (3.2-fold) compared
with the controls (Fig. 3A and B). However, in the bDKO
mice, pAKT-S473 was decreased to the same low level seen
in the bRicKO mice. Surprisingly, the phosphorylation of
AKT-T308 in the bDKO mice was 11.8-fold higher than that
of the controls (P , 0.01), greatly exceeding the 3.7-fold
increase observed in the bPtenKO animals (P , 0.01).
Downstream targets of AKT were also signiﬁcantly af-
fected by the loss of Rictor or Pten. Speciﬁcally, the
amount of p27 was decreased by 50% in bPtenKO islets but
increased in the bDKO mice to a level similar to that of the
controls (Fig. 3C and D). Similarly, the amount of FoxO1
was normal in bPtenKO islets but signiﬁcantly increased in
the bDKO mice. Other signaling downstream of AKT, such
as S6 phosphorylation (Fig. 3E), which is mediated
through mTORC1, was increased in both bPtenKO (P ,
0.05) and bDKO islets (P = 0.07). These data indicate that
in pancreatic b-cells the phosphorylation of AKT-S473 is
dependent on Rictor/mTORC2 signaling. Notably, the in-
creased phosphorylation of AKT-T308 that occurs with
the loss of Rictor/mTORC2 in bDKO suggests that either
Rictor/mTORC2 itself or a downstream target of pAKT-S473
has an inhibitory effect on the PDK1-mediated phosphory-
lation of AKT-T308.
Ablation of both Rictor/mTORC2 or Pten changes
FoxO1 cellular distribution. On phosphorylation by
AKT, FoxO1, which normally resides in the nucleus where
it inhibits b-cell proliferation, enters the cytoplasm where
it is ubiquitinated and degraded (22,23). Thus, to de-
termine whether FoxO1 cellular distribution was affected
by the absence of Rictor or Pten in b-cells, we studied the
subcellular localization of FoxO1 in b-cells (Fig. 4 and
Supplementary Fig. 5). As expected, FoxO1 was mostly
located in nuclei of b-cells of control mice (Fig. 4A and E).
Moreover, in the bRicKO mice nuclear FoxO1 levels were
further increased (Fig. 4B and F and Supplementary Fig. 5)
compared with Dlox b-cells. However, FoxO1 was shifted
almost entirely to the cytoplasm in the bPtenKO mice (Fig.
4C and G and Supplementary Fig. 5). In bDKO mice (Fig.
4D and H and Supplementary Fig. 5), the nuclear locali-
zation of FoxO1 in b-cells was restored. Similarly, islets
from bRicKO mice also showed diminished nuclear Pdx1
labeling (Supplementary Fig. 6), whereas bDKO islets
maintained a normal nuclear localization pattern. These
ﬁndings suggest that the mTORC2-dependent phosphory-
lation of AKT-S473 regulates FoxO1 activity by changing
its cellular distribution and that this regulation is in-
dependent of the increased phosphorylation of AKT-T308
in Pten null pancreatic b-cells.
Rictor or Pten deletion alters the gene expression
proﬁle of many pancreatic genes. To explore the con-
sequences on gene expression of deleting Rictor or Pten in
b-cells, we assessed the mRNA transcriptional proﬁles of
43 genes in pancreatic islets from bRicKO, bPtenKO, and
bDKO mice as shown in Fig. 5A. Among genes that regu-
late cell cycle progression, we found that the expression of
p27 was decreased by approximately 50% in the bPtenKO
mice, CDK4 was decreased 25% in the bRicKO group, and
p21 was increased in all mutant mice, and was most highly
expressed in the bPtenKO animals. These changes were
partially (p27 and p21) or totally restored (CDK4) in the
bDKO mice (Fig. 5B). Among genes that play a role in insulin
secretion, Connexin-36 (24,25) and Vamp-2 (26) were di-
minished in the bRicKO mice. In contrast, Syntaxin-1 (26)
was unaffected in the bRicKO mice but increased in bDKO
b-cells (Fig. 5C). Despite unchanged Pdx1 expression, the
expression of MafB was elevated in both the bRicKO and
bDKO mice, and Neurog3 was increased in bRicKO animals
(Fig. 5D).
DISCUSSION
Mice lacking b-cell Rictor/mTORC2 exhibit impaired glu-
cose tolerance due to a combination of reduced pancreatic
insulin content and impaired glucose-stimulated insulin
secretion. The reduced pancreatic insulin content is due to
a lower b-cell mass brought on by diminished rates of
FIG. 4. Differential cellular distribution of FoxO1 in pancreatic b-cells
with different genotypes. A–D: Immunolabeling of FoxO1 (red) in
pancreatic islets. E–H: Double immunolabeling of FoxO1 (red) and in-
sulin (green). A and E: FoxO1 immunolabeling in control islets showing
its localization mainly in the nucleus. B and F: FoxO1 immunolabeling
in bRicKO islets. bRicKO islets showing a more intense nuclear FoxO1
staining than the controls. C and G: FoxO1 immunolabeling in bPtenKO
islets showing the lack of nuclear FoxO1 accumulation. D and H: FoxO1
immunolabeling in bDKO islets. Nuclear staining pattern in bDKO
islets is similar to bRicKO islets. Scale bar = 20 mm. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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a molecular level, the absence of Rictor/mTORC2 impairs
PI3K signaling through AKT by blocking the phosphorylation
of AKT at S473. This leads to a reduction in AKT activity,
thereby suppressing cell division, by both activating p27 and
increasing the accumulation of FoxO1 in the nucleus.
The loss of mTORC2-mediated phosphorylation of AKT
seems to have less of an impact on b-cell proliferation than
does the loss of PDK1 (7), as summarized in Table 1,
although this is difﬁcult to accurately assess between
the different studies. Our ﬁndings indicate that signaling
through mTORC2/pAKT-S473 promotes b-cell proliferation
FIG. 5. Deletion of Rictor or Pten changed gene expressions of pancreatic transcription factors and genes related to cell cycle and insulin secretion
in pancreatic islets. A: Heat map representing comparison of gene expression proﬁle determined by TaqMan RT-PCR and calculated by -DDCT
method with 18S RNA as the internal control. A total of 43 genes from the four categories indicated on the far left were analyzed. Gene expression
abundance was shown in varying color levels of red and green, with red representing upregulation, green representing downregulation, and black
representing the level in the control group. B: Comparisons of some cell cycle-related genes: p27, CDK4, and p21 expression proﬁles were sig-
niﬁcantly different among all genotypes. C: Comparison of genes regulating insulin secretion machinery; Vamp-2, Connexin-36,a n dSyntaxin-1
had differential gene expression patterns in all four genotypes. D: Comparisons of critical pancreatic transcription factors; Pdx1, MafB, and
Neurog3 showed differential expression patterns in all four genotypes. Control is Dlox.* P < 0.05; **P < 0.01. Data are presented as mean 6 SEM.
Three mice were analyzed for each genotype.
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deed, the lack of Rictor/mTORC2 resulted in lower rates of
both b-cell proliferation, even in the presence of a 12-fold
increase in pAKT-T308, as occurs in the bDKO mice. Thus,
mTORC2-mediated phosphorylation of AKT-S473 clearly
contributes to the maintenance of b-cell mass, even if quan-
titatively less than that of PDK1/pAKT-T308.
Rictor/mTORC2 is also important for normal b-cell
function, as shown by approximately 70% reduction in
glucose-stimulated insulin secretion bRicKO islets. The
reduced insulin secretion is likely due to impaired insulin
biosynthesis because there was a 50% reduction in pan-
creatic insulin content (Fig. 2B) but only a 30% decrease in
b-cell mass (Fig. 2A). However, insulin exocytosis also
seems to be impaired. Consistent with this are 1) the cyto-
plasmic translocation of Pdx1 (Supplementary Fig. 6), 2)
the nuclear accumulation of FoxO1 in bRicKO islets (Fig. 4
and Supplementary Fig. 5), and 3) the impaired expression
of several genes involved in insulin exocytosis, such as
Vamp-2 and Connexin-36 (Fig. 5C). Pdx1 is an important
determinant of b-cell function that is known to be regu-
lated by PI3K/ATK signaling (23,27,28). It is also a direct
downstream target of FoxO1 (22). Indeed, at least two
prior studies have shown that PI3K/AKT signaling stim-
ulates insulin biosynthesis and secretion (5,29). Thus, our
study provides additional evidence that Rictor/mTORC2 is
important for the PI3K-mediated regulation of b-cell func-
tion via the previously reported AKT/FoxO1/Pdx1 pathway
(22,23,27,28).
The phenotype of the bDKO mice, although complex,
was highly informative. Although the near reversal in the
bDKO mice of the impairments of b-cell proliferation and
insulin secretion observed in the bRicKO mice might have
been expected, we were surprised to ﬁnd that the b-cells
of bDKO mice were larger in size than the other genotypes.
Although we only assessed changes in b-cell area, our
measurements predict an even larger increase in the actual
volume of these cells. The increase in cell size correlates
with an ~12-fold increase in pAKT-T308 in the bDKO mice,
more than the increase in both b-cell size and AKT-T308
phosphorylation in the bPtenKO animals. Thus, we pro-
pose that the marked increase in AKT-T308 phosphorylation
that occurs in the absence of Rictor/mTORC2 is caused by
the disruption of a negative feedback loop that is essential
for maintaining normal-sized b-cells.
The simultaneous reduction in b-cell proliferation and
enlargement of b-cells in the bDKO mice, compared with
bPtenKO mice, is most easily explained if the two phos-
phorylation sites in AKT have different downstream
effects. Indeed, our ﬁndings and those of others (7) are
consistent with pAKT-S473 principally affecting the rate
of b-cell proliferation and pAKT-T308 mainly affecting
b-cell size. Our analysis of downstream signaling events
revealed that the changes in b-cell proliferation were
correlated with alterations in pAKT-S473, FoxO1, and p27.
Both FoxO1 and p27 protein amount, and FoxO1 nuclear
localization were increased in the bDKO mice, even
though these mice have an ~12-fold elevation of pAKT-
T308 and are consistent with previous studies showing
that pAKT-S473 exclusively activates FoxO1 signaling
(11,12). Because both FoxO1 and p27 are negatively
regulated by AKT, and both serve as critical cell cycle
inhibitors for pancreatic b-cells (30,31), the increased
amount of these proteins in the bRicKO mice would be
expected to cause a reduction in b-cell proliferation, and
thus mass.
Similarly, the notion that pAKT-T308 may regulate b-cell
size is supported by other studies demonstrating that the
deletion of PDK1 in various tissues (7,32–36), as well as
the whole embryo (37), both impairs mTORC1/S6 signaling
and lowers cell size despite a reciprocal increase in pAKT-
S473. A role for AKT/mTORC1 signaling in the regulation
of b-cell size has clearly been shown in studies in which
mTORC1/S6 signaling has been augmented, either by de-
leting TSC1/TSC2 (38) or by overexpressing Rheb (39).
Although we found an increase of pS6 in both bPtenKO
and bDKO cells, the increment of pS6 was less than that
of pAKTS308, suggesting other downstream signaling of
pAKT-T308 or mTORC1 might also contribute to cell size
regulation.
When prior studies are considered (40), our ﬁndings are
consistent with the existence of dual, reciprocal feedback
signaling loops involving AKT (Fig. 6) that, together, func-
tion to maintain a tight balance between cell proliferation
FIG. 6. Model for the differential roles of the two AKT phosphorylation
sites in regulating pancreatic b-cell size and proliferation. A: Balance
between b-cell size and cell number is maintained by the site-speciﬁc
phosphorylation of AKT at T308 and S473 and dual negative feedback
loops. B: PI3K/AKT signaling is activated by growth factors/insulin
binding to their receptors. In the case of insulin, insulin receptor ac-
tivation stimulates insulin receptor substrate, which then activates
PI3K and phosphorylation of PI2P to PI3P. The intracellular accumu-
lation of PI3P then stimulates PDK1 and mTORC2 to phosphorylate
AKT at T308 and S473, respectively. AKT is phosphorylated at both
T308 and S473. Phosphorylation of AKT-T308 (pAKT-T308) selectively
targets mTORC1/S6, whereas phosphorylation of AKT-S473 (pAKT-
S473) selectively targets FoxO1/p27 signaling. These AKT phosphor-
ylations mutually regulate to maintain b-cell mass homeostasis. Solid
arrows indicate the known signaling events; dashed lines indicate
a newly proposed inhibitory feedback mechanism. CM, cell membrane;
IR, insulin receptor; IRS, insulin receptor substrate; PH, pleckstrin
homology domain.
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causes a negative feedback inhibition on pAKT-S473 and,
reciprocally, mTORC2/pAKT-S473 signaling inhibits pAKT-
T308. Although signaling through pAKT-T308 to mTORC1
may explain how the ﬁrst feedback loop is mediated (10,40),
the mechanism whereby pAKT-S473 signals to FoxO1 to
inhibit pAKT-T308 is less certain. We suggest that the
upregulation of FoxO1, which occurs in the Rictor-null
b-cells, releases an inhibition of PI3K/PDK1/pAKT-T308
signaling. If so, this would position FoxO1 as a positive reg-
ulator of PI3K/PDK1/pAKT-T308. However, because FoxO1
has not been demonstrated to play any role in the regulation
of PI3K/PDK1/pAKT-T308 in b-cells, this possibility, for the
time being, is speculative.
In any case, although some aspects of this model are
unproven, it provides an appealing explanation for our
ﬁndings and suggests mechanisms whereby the site-speciﬁc
phosphorylation of AKT may exert differential effects on
b-cell proliferation and cell size. In this model (Fig. 6B), the
increase in pAKT-S473 causes the downregulation of both
FoxO1 and p27, which, through inhibition of PI3K/PDK1/
pAKT-T308, induces cell proliferation. Conversely, an in-
crease in pAKT-T308, brought about by the upregulation
of FoxO1 and p27, slows cell proliferation and stimulates
an expansion in the size, or cellular hypertrophy, of b-cells.
Thus, by exerting distinct downstream signaling effects in
response to phosphorylation at either T308 or S473, AKT
serves as a focal point for maintaining a balance between
b-cell proliferation and cell size in response to stimuli that
increase b-cell mass.
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